AU2002225730A1 - Compounds - Google Patents
CompoundsInfo
- Publication number
- AU2002225730A1 AU2002225730A1 AU2002225730A AU2573002A AU2002225730A1 AU 2002225730 A1 AU2002225730 A1 AU 2002225730A1 AU 2002225730 A AU2002225730 A AU 2002225730A AU 2573002 A AU2573002 A AU 2573002A AU 2002225730 A1 AU2002225730 A1 AU 2002225730A1
- Authority
- AU
- Australia
- Prior art keywords
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24919900P | 2000-11-16 | 2000-11-16 | |
| US60249199 | 2000-11-16 | ||
| PCT/US2001/043994 WO2002040468A1 (en) | 2000-11-16 | 2001-11-14 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002225730A1 true AU2002225730A1 (en) | 2002-05-27 |
Family
ID=22942445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002225730A Abandoned AU2002225730A1 (en) | 2000-11-16 | 2001-11-14 | Compounds |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040039198A1 (en) |
| EP (1) | EP1349851A4 (en) |
| JP (1) | JP2004517068A (en) |
| AU (1) | AU2002225730A1 (en) |
| WO (1) | WO2002040468A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10123163A1 (en) | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituted cyclohexane-1,4-diamine derivatives |
| AR039241A1 (en) * | 2002-04-04 | 2005-02-16 | Biogen Inc | HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME |
| US7244743B2 (en) | 2002-06-05 | 2007-07-17 | Solvay Pharmaceuticals Gmbh | Non-peptidic BRS-3 agonists |
| EP1575506A4 (en) * | 2002-07-25 | 2008-04-23 | Scios Inc | Methods for improvement of lung function using tgf-beta inhibitors |
| GB0217783D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| WO2004013135A1 (en) * | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| PL375974A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| BR0314286A (en) | 2002-09-18 | 2005-08-02 | Pfizer Prod Inc | Isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
| CN1681501A (en) | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors |
| MXPA05002332A (en) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors. |
| EA200500378A1 (en) | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | NEW IMIDAZOL COMPOUNDS AS A TRANSFORMING GROWTH FACTOR INHIBITORS (TGF) INHIBITORS |
| US20040192583A1 (en) * | 2002-12-19 | 2004-09-30 | Satyanarayana Medicherla | Treatment of obesity and associated conditions with TGF-beta inhibitors |
| PA8595001A1 (en) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF) |
| GB0326963D0 (en) * | 2003-11-19 | 2003-12-24 | Glaxo Group Ltd | Compounds |
| RU2367661C2 (en) | 2004-03-05 | 2009-09-20 | Тайсо Фармасьютикал Ко., Лтд. | Thiazole derivatives |
| US20070275968A1 (en) * | 2004-09-07 | 2007-11-29 | Hitoshi Kurata | Substituted Biphenyl Derivative |
| WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| RS55735B1 (en) | 2007-08-03 | 2017-07-31 | Summit (Oxford) Ltd | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| WO2009146301A1 (en) * | 2008-05-27 | 2009-12-03 | Yale University | TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE |
| DK2855665T3 (en) | 2012-05-30 | 2019-11-04 | Univ Cornell | PROVISION OF FUNCTIONAL AND RESISTANT ENDOTEL CELLS FROM HUMAN AMNION FLUID DERIVATED CELLS |
| ES2791778T3 (en) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigation of tissue damage and fibrosis through anti-LTBP4 antibodies |
| CN105229144A (en) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | By combination genetic engineering and chemical engineering via forward programming produce liver cell |
| US10961531B2 (en) | 2013-06-05 | 2021-03-30 | Agex Therapeutics, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| PE20171789A1 (en) * | 2015-03-02 | 2017-12-28 | Bristol Myers Squibb Co | INHIBITORS OF THE TRANSFORMATION GROWTH FACTOR BETA (TGF-BETA) |
| MX2021006831A (en) * | 2018-12-11 | 2021-07-02 | Theravance Biopharma R&D Ip Llc | Alk5 inhibitors. |
| CN113347990A (en) | 2018-12-21 | 2021-09-03 | 西北大学 | Use of annexin in prevention and treatment of muscularis damage |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| US11795160B2 (en) | 2019-02-22 | 2023-10-24 | Insilico Medicine Ip Limited | Kinase inhibitors |
| US11590116B2 (en) | 2019-11-22 | 2023-02-28 | Theravance Biopharma R&D Ip, Llc | Substituted pyridines and methods of use |
| AR122711A1 (en) * | 2020-06-25 | 2022-09-28 | Alchemedicine Inc | HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1d AND/OR KINASE 5 ACTIVIN RECEPTOR TYPE |
| TW202245753A (en) | 2021-02-24 | 2022-12-01 | 香港商英科智能有限公司 | Analogs for the treatment of disease |
| WO2024041555A1 (en) * | 2022-08-24 | 2024-02-29 | Insilico Medicine Ip Limited | Methods of manufacturing kinase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940486A (en) * | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
| JPH09124640A (en) * | 1995-08-25 | 1997-05-13 | Nippon Soda Co Ltd | Pyridylimidazole compound, production thereof and fungicide for agricultural and horticultural use |
| DE60001229T2 (en) * | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp | triarylimidazoles |
| AR029803A1 (en) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | IMIDAZOLS REPLACED WITH PIRIDILE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
| GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
-
2001
- 2001-11-14 JP JP2002543479A patent/JP2004517068A/en not_active Withdrawn
- 2001-11-14 US US10/416,761 patent/US20040039198A1/en not_active Abandoned
- 2001-11-14 AU AU2002225730A patent/AU2002225730A1/en not_active Abandoned
- 2001-11-14 WO PCT/US2001/043994 patent/WO2002040468A1/en not_active Application Discontinuation
- 2001-11-14 EP EP01995214A patent/EP1349851A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20040039198A1 (en) | 2004-02-26 |
| WO2002040468A1 (en) | 2002-05-23 |
| JP2004517068A (en) | 2004-06-10 |
| EP1349851A4 (en) | 2004-09-08 |
| EP1349851A1 (en) | 2003-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002225730A1 (en) | Compounds | |
| AU2002218266A1 (en) | Novel indanylidene compounds | |
| AU2001254546A1 (en) | Aminopiperidines | |
| AU2001292518A1 (en) | Novel compounds | |
| AU2001239310A1 (en) | Decahydro-isoquinolines | |
| AU2001220246A1 (en) | Neckphone | |
| AU2001266345A1 (en) | Five-membered-ring compound | |
| AU2001258349A1 (en) | Bisacylguanidine | |
| AUPQ661800A0 (en) | Insulin-potentiating compounds | |
| AU2001239765A1 (en) | Novel compounds | |
| AU2001246998A1 (en) | Novel compounds | |
| AU2001253362A1 (en) | Novel compounds | |
| AU2001265871A1 (en) | Substituted sulfonylaminopyrimidines | |
| AU2002231077A1 (en) | Novel compounds | |
| AU2001254731A1 (en) | Substituted phenyluracils | |
| AU2001256964A1 (en) | Novel compounds | |
| AU2001258255A1 (en) | Substituted benzoylcyclohexenones | |
| AU2002225724A1 (en) | Motilide compounds | |
| AU2001220281A1 (en) | Rollerboard for road-skiing | |
| AU2002217285A1 (en) | Compounds | |
| AU2001230689A1 (en) | Novel compounds | |
| AU2001246864A1 (en) | Hypotensors | |
| AU2002221923A1 (en) | Novel compounds | |
| AU2002216060A1 (en) | Novel compounds | |
| AU2001276890A1 (en) | Novel compounds |